Polyrizon (NASDAQ:PLRZ) Shares Up 1.7% – What’s Next?

Shares of Polyrizon Ltd. (NASDAQ:PLRZ) were up 1.7% during trading on Tuesday . The company traded as high as $13.92 and last traded at $13.49. Approximately 18,732 shares were traded during trading, a decline of 48% from the average daily volume of 35,779 shares. The stock had previously closed at $13.26.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Polyrizon from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 13th. Wall Street Zen upgraded Polyrizon from a “sell” rating to a “hold” rating in a research report on Sunday, June 7th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Polyrizon Stock Performance

The company has a 50 day moving average of $13.56 and a 200-day moving average of $13.56.

Institutional Trading of Polyrizon

An institutional investor recently bought a new position in Polyrizon stock. Jane Street Group LLC purchased a new stake in shares of Polyrizon Ltd. (NASDAQ:PLRZ) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned about 1.35% of Polyrizon at the end of the most recent quarter.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.